tradingkey.logo

Lexicon Pharmaceuticals Inc <LXRX.OQ> expected to post a loss of 10 cents a share - Earnings Preview

ReutersMay 9, 2025 11:14 PM
  • Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to show a rise in quarterly revenue when it reports results on May 13 for the period ending March 31 2025

  • The The Woodlands Texas-based company is expected to report a 25.0% increase in revenue to $1.413 million from $1.13 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Lexicon Pharmaceuticals Inc is for a loss of 10 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.20​, above​ its last closing price of $0.70. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.13

-0.13

-0.09

Beat

29.3

Sep. 30 2024

-0.17

-0.16

-0.18

Missed

-9.4

Jun. 30 2024

-0.19

-0.19

-0.17

Beat

9.9​

Mar. 31 2024

-0.20

-0.20

-0.20

Met

-1.3

​​Dec. 31 2023

-0.22

-0.22

-0.20

Beat

7.9

Sep. 30 2023

-0.21

-0.21

-0.21

Met

2.2​

Jun. 30 2023

-0.17

-0.17

-0.22

Missed

-25.9

Mar. 31 2023

-0.18

-0.18

-0.17

Beat

5.2

This summary was machine generated May 9 at 23:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI